## Company Profile World Courier Tasimacilik ve Loj.Hizm.Tic.Ltd.Sti. — local Turkish arm/operation of World Courier, a specialised global logistics company focused on temperature‑sensitive and time‑critical shipments for the life‑sciences sector. Services (expected at an Istanbul depot): GDP‑compliant cold‑chain handling, clinical‑trial material movement, temperature‑controlled air freight and express, customs clearance for pharma, warehousing and depot services. Market position: niche/specialist freight forwarder within the global World Courier network, serving sponsors, manufacturers and distributors of pharmaceuticals, biologics and clinical‑trial supplies in Turkey and cross‑border to MENA, Europe and CIS markets. Scale: presence as an Istanbul/Turkey depot (contact: turkey-depot@worldcourier.com) integrated into a global specialist logistics platform; likely small local team with access to global capacity and expertise. ## Pain Points 1) Rising volume of temperature‑sensitive pharma (biologics, vaccines, sterile injectables) from Turkey with limited visible origin capacity windows — clients will increasingly need guaranteed, end‑to‑end sourcing and air uplift bookings timed around seasonal peaks (Q4–Q1) and ad‑hoc vaccine campaigns. 2) Clinical‑trial customers and exporters need faster origin sourcing and cross‑border buyer discovery into MENA/CIS/EU markets (growing export demand) plus documentation and cold‑chain orchestration — creating gaps between commercial sourcing and reliable delivery. 3) Periodic capacity tightness on Europe–Middle East–Asia corridors despite new hub investments (FedEx/ iGA/Turkish Cargo), meaning ad‑hoc shipments face rate spikes and booking risk; World Courier’s customers need a channel that can pre‑qualify exporters/importers and coordinate bookings/booking windows proactively. ## Intel Summary === MULTI-DIMENSION RESEARCH === === 1. [MARKET EVENTS] – Turkey pharmaceutical logistics / Istanbul cold chain / clinical trial hubs (focus on 2025–2026, esp. last 90 days) === **Cold‑chain & healthcare logistics capacity expansions in Istanbul** - **DHL Supply Chain Türkiye – new “Asya 1” multi‑user facility in Tuzla, Istanbul (May 4, 2026)** - Location: Tuzla, on the Asian side of Istanbul, close to **Sabiha Gökçen International Airport (SAW)**. - Positioning: Designed as a **multi‑industry hub with a strong focus on healthcare logistics**, explicitly compliant with **GDP (Good Distribution Practices) and GMP standards** for pharmaceuticals. - Functions: End‑to‑end logistics, including warehousing, value‑added services and transport management; the press release highlights “high value‑added and reliable solutions in healthcare logistics,” implying temperature‑controlled pharma flows integrated into the broader network. - Strategic angle: Sits within DHL’s regional network and is described as a “significant investment” aligned with **growing supply chain needs** across Turkey and neighboring regions—relevant for both commercial pharma and clinical‑trial logistics. ([dhl.com](https://www.dhl.com/tr-en/home/press/press-archive/2026/dhl-supply-chain-turkiye-opens-asia-1-facility.html?utm_source=openai)) - **Arvato Supply Chain Solutions – expanded logistics footprint in Istanbul (new center opened 2025; automation ramping in 2026)** - Arvato (Bertelsmann subsidiary) opened a new logistics center in Istanbul, adding to a network of **9 facilities and >300,000 m² warehouse space** in Turkey. ([airfreight.news](https://airfreight.news/articles/full/arvato-opens-new-logistics-center-in-istanbul?utm_source=openai)) - Current focus: omnichannel B2B/B2C fulfillment (including healthcare and cosmetics in its global portfolio). - Timing signal: The article states that **from 1H 2026 the site will introduce automation for cosmetics handling**—not pharma‑specific but indicative of continuing capex into higher‑value, temperature‑sensitive and regulated categories in Istanbul’s logistics ecosystem. ([airfreight.news](https://airfreight.news/articles/full/arvato-opens-new-logistics-center-in-istanbul?utm_source=openai)) - **Turkey pharma cold chain infrastructure – national market signals (2024–2030 outlook, cited 2026)** - A recent commercial research note on **“Turkey Cold Chain Infra for Pharma”** identifies **Istanbul, Ankara and Izmir as the dominant cities** by cold‑chain capacity for pharma. - It notes **government allocation of around USD 1.5 billion for future healthcare infrastructure improvements, including cold chain logistics**, and estimates **c. USD 500 million in capital requirements** for new cold chain facilities and technology upgrades (IoT monitoring, automation). ([kenresearch.com](https://www.kenresearch.com/turkey-cold-chain-infra-for-pharma-market?utm_source=openai)) - The study stresses rapid growth in cold‑chain demand driven by biologics, vaccines and temperature‑sensitive specialty drugs—creating sustained demand for expanded warehouse and last‑mile temperature‑controlled capacity in metropolitan hubs like Istanbul. ([kenresearch.com](https://www.kenresearch.com/turkey-cold-chain-infra-for-pharma-market?utm_source=openai)) **Istanbul as a logistics & clinical‑trial gateway** - **iGA Istanbul Airport cargo hub** - A 2026 ITS Europe Congress briefing on Istanbul’s role as a logistics gateway notes: - **iGA cargo hub footprint ~1.4 million m²**, already hosting **Turkish Cargo, DHL, UPS** and others. - The city lies within **five‑hour flight time of Europe, the Middle East, Central Asia and North Africa**, reinforcing its suitability for time‑ and temperature‑critical pharma. - Reference to **forthcoming freight consolidation hubs within Istanbul’s Sustainable Urban Mobility Plan (SUMP)**, which should streamline urban distribution and last‑mile logistics (relevant for clinical‑trial sample movements between hospitals/university clinics and airports). ([2026.itseuropeancongress.com](https://2026.itseuropeancongress.com/about/istanbul-bridging-innovation-at-the-crossroads-of-continents/strategic-market-investment-gateway?utm_source=openai)) - **FedEx global air transit facility at Istanbul Airport (inaugurated September 4, 2025)** - FedEx has opened a **new global air transit facility at Istanbul Airport (IST)**, explicitly described as strengthening Türkiye’s position as a global logistics node. ([newsroom.fedex.com](https://newsroom.fedex.com/newsroom/europe-english/fedex-inaugurates-new-global-air-transit-facility-at-istanbul-airport-elevating-turkiyes-position-in-global-logistics?utm_source=openai)) - Although not pharma‑exclusive, this incrementally increases **time‑definite air cargo capacity** (including temperature‑sensitive shipments via FedEx’s healthcare solutions) and shortens transit times between Europe, Middle East and Asia—supporting both commercial pharma and clinical‑trial logistics corridors. **Clinical‑trial hubs – directional evidence (Turkey / Istanbul)** - Recent **Turkey pharma sector reports** emphasize the government’s aim to grow **R&D and clinical research**, including incentives for multinational clinical trials, but they do not yet list 2026‑specific “new clinical‑trial hub facilities” in Istanbul with concrete square‑meter or capacity data. ([aifd.org.tr](https://www.aifd.org.tr/wp-content/uploads/2024/12/20241105_Turkish-pharma-sector-report-2024_Summary.pdf?utm_source=openai)) - Given: - Istanbul’s concentration of **university hospitals** and **city hospitals** - The expansion of **GDP/GMP‑compliant logistics nodes (DHL, Arvato, iGA cargo, FedEx transit hub)** - And targeted **government healthcare and cold‑chain funding (~USD 1.5 billion)** …Istanbul is effectively consolidating its role as Turkey’s main **clinical‑trial logistics hub**, even if explicit “clinical‑trial‑dedicated warehouses” are not separately reported in the last 90 days. **Implications for 2026–2028** - Cold‑chain and value‑added pharma logistics capacity in Istanbul is **clearly expanding**, with: - New multi‑user, GDP‑compliant facilities (DHL Asya 1). - Larger integrated warehouse platforms (Arvato’s network, >300,000 m²; nine facilities). - Airport‑side air cargo and express capacity upgrades (FedEx transit facility, iGA cargo plans). - This supports: - Higher throughput of **temperature‑sensitive vaccines, biologics and clinical‑trial materials**. - Positioning Istanbul as a **regional distribution and trial‑support hub** for the broader Europe–Middle East–North Africa (EMENA) region. **Sources – Dimension 1** DHL Supply Chain Türkiye Asya 1 facility press release; Arvato Istanbul logistics center coverage; Turkey pharma cold chain infrastructure market note; ITS Europe 2026 Istanbul logistics gateway briefing; FedEx Istanbul global air transit press release; Turkish investment/FDI newsletter; Turkish pharma sector reports. ([dhl.com](https://www.dhl.com/tr-en/home/press/press-archive/2026/dhl-supply-chain-turkiye-opens-asia-1-facility.html?utm_source=openai)) === 2. [COMMODITY TRENDS] – Turkey pharmaceutical exports, with emphasis on biologics & vaccines (2026) === **Overall pharma export trajectory** - **Historical growth** - A 2024 Turkish innovative pharma association report (AIFD) indicates that **Turkey’s pharmaceutical exports grew at a CAGR of ~12.6% over the last decade** up to 2023. ([aifd.org.tr](https://www.aifd.org.tr/wp-content/uploads/2024/12/20241105_Turkish-pharma-sector-report-2024_Summary.pdf?utm_source=openai)) - **Recent export value levels (2025/early 2026)** - TradingEconomics data show **Turkey’s exports of pharmaceutical products** (HS 30) currently updated through early **2026**; monthly values in late 2025–early 2026 fluctuate roughly in the **USD 200–300 million/month** range, with a visible upward trend versus pre‑pandemic levels. ([tradingeconomics.com](https://tradingeconomics.com/turkey/exports/pharmaceutical-products?utm_source=openai)) - Sector commentary (xPharma Turkey, Feb 8, 2026) highlights that **Iraq, Saudi Arabia, UAE, Egypt and Libya** are major markets for Turkish pharma exports and notes that exports are **expected to “continue their growth trajectory” in 2026**, supported by R&D and biotech investments. ([xpharma.com.tr](https://xpharma.com.tr/en/turkey-pharmaceutical-export?utm_source=openai)) - **Chemicals and pharma as part of wider chemicals complex** - According to the Istanbul Chemicals and Chemical Products Exporters’ Association (İKMİB), Turkish chemical exports (which include pharmaceuticals) reached **~USD 11 billion in Jan–Apr 2026**, with April alone at **USD 3.1 billion**. The sector is targeting **USD 35 billion in chemical exports by 2026**. While this aggregates more than pharmaceuticals, it underscores a strong export push in chemicals and life‑science‑adjacent categories. ([chemexworld.com](https://chemexworld.com/en/news/news/turkish-chemical-exporters-target-35-billion-in-2026?utm_source=openai)) **Biologics & vaccines – positioning and growth signals** - **Policy and strategy** - Turkey’s 2024–2028 pharma and industrial strategies emphasize **biotechnology and biologics** as priority segments, targeting a higher share of **medium‑high technology exports** and explicitly referencing biotechnology investments in the pharmaceutical sector as part of the 2026–2028 Export Strategy Action Plan. ([toko.com.tr](https://www.toko.com.tr/en/blog/turkey-export-potential-2026?utm_source=openai)) - **Export mix and technology intensity** - The AIFD sector report notes that **high‑value medicines (including biologics and specialty drugs) already constitute a rising share of exports**, with **58% of medicine exports concentrated in 20 main destination countries**, typically markets that import higher‑priced innovative medicines. ([aifd.org.tr](https://www.aifd.org.tr/wp-content/uploads/2024/12/20241105_Turkish-pharma-sector-report-2024_Summary.pdf?utm_source=openai)) - **Biotech investment driving future exports** - xPharma’s February 2026 analysis points to **increasing investments in biotechnology and R&D** and concludes that these will **support further growth in pharma exports**, particularly to MENA markets. Although the piece does not break out separate biologics vs. small‑molecule export values, it frames **biopharmaceuticals and vaccines** as key beneficiaries of R&D and manufacturing upgrades (sterile injectables, fill‑finish lines, etc.). ([xpharma.com.tr](https://xpharma.com.tr/en/turkey-pharmaceutical-export?utm_source=openai)) **Quantitative gaps / what is *not* yet visible** - Open‑source trade statistics (UN Comtrade 2024–2025 releases and secondary citations) typically break pharma into HS‑2 (30) or HS‑4 (e.g., 3002 – human/animal blood; 3003/3004 – medicaments), but **recent public data for 2025–2026 rarely separate “biologics” or “vaccines” as a clear export sub‑category for Turkey**. - As of May 2026: - We can **quantify total pharma exports and see clear growth** (low‑to‑mid double‑digit CAGR, rising monthly values). ([tradingeconomics.com](https://tradingeconomics.com/turkey/exports/pharmaceutical-products?utm_source=openai)) - We **cannot yet credibly state** a specific 2026 **biologics/vaccines export volume, market share (%) or growth rate** from open sources; such figures are either paywalled in proprietary databases or still in compilation at official statistics agencies. **Inferred directional view for 2026** Combining official and industry sources: - **Total pharma exports**: Rising, with **2025–2026 YoY growth likely in the high single‑ to low double‑digit range**, in line with recent historical CAGR (~12–13%). ([tradingeconomics.com](https://tradingeconomics.com/turkey/exports/pharmaceutical-products?utm_source=openai)) - **Geographic orientation**: - **MENA and Near‑abroad** (Iraq, Saudi Arabia, UAE, Egypt, Libya, CIS) remain the primary growth markets, with Turkey exporting mainly **generic and branded generics**, but increasingly **higher‑value dosage forms and sterile injectables**. ([xpharma.com.tr](https://xpharma.com.tr/en/turkey-pharmaceutical-export?utm_source=openai)) - **Biologics & vaccines**: - Capacity for **biosimilars, vaccines, and other biologics** is expanding via local manufacturing and fill‑finish projects; exports of these products likely **grow faster than the overall pharma export average**, but off a smaller base. - Policy (export‑oriented biotech incentives) and **cold‑chain infrastructure build‑out** (see Dimension 1) are aligned to support higher‑margin biologic and vaccine exports over 2026–2028. **Sources – Dimension 2** AIFD Turkish pharma sector report (2024 summary); TradingEconomics Turkey pharma exports; xPharma Turkey export analysis (Feb 2026); Turkey export potential / 2026–2028 Export Strategy references; Turkish chemical exporters’ association and sector news. ([toko.com.tr](https://www.toko.com.tr/en/blog/turkey-export-potential-2026?utm_source=openai)) === 3. [TIMING SIGNALS] – Istanbul air cargo capacity, rates, and seasonal peaks (2026, Europe–Middle East) === **Global & regional air cargo backdrop (2025–2026)** - **Global demand & capacity** - IATA’s **February 2026 Air Cargo Market Analysis** reports **global cargo tonne‑kilometer (CTK) demand up 11.2% YoY**, while **available cargo tonne‑kilometers (ACTK) rose 8.5% YoY**—demand growing faster than capacity. The **Middle East saw 16.6% YoY demand growth**, leading most regions. ([iata.org](https://www.iata.org/en/publications/economics/reports/air-cargo-market-analysis-february-2026/?utm_source=openai)) - A separate IATA analysis for **December 2025** highlights robust growth in the **Europe–Asia corridor (+12.2% YoY)** and notes significant contributions from Europe–Middle East and Middle East–Asia trade lanes, which are key flows touching Istanbul. ([mtsinsights-assets.s3.amazonaws.com](https://mtsinsights-assets.s3.amazonaws.com/media/summaries/att/iata-air-cargo-market-analysis/2026/01/29/c63bc21f-9a82-478-ad7e-076f57e916a8.pdf?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIARB7EFOVKWBL5S67B%2F20260306%2Fus-east-2%2Fs3%2Faws4_request&X-Amz-Date=20260306T101745Z&X-Amz-Expires=3600&X-Amz-Signature=88c2c141d566a03a283bea11ee7ed8b9ff7541b2ee27c32ccb3c0a71b7623aa2&X-Amz-SignedHeaders=host&response-content-disposition=inline&response-content-type=application%2Fpdf&utm_source=openai)) - Transport Research Advisory’s early‑2026 freighter outlook shows that, **apart from Far East–North America, air cargo capacity increased across major trade lanes in January 2026**, including **“Other Europe to/from Middle East”**, confirming a step‑up in belly and freighter capacity in the corridors where Istanbul is a major hub. ([istat.org](https://www.istat.org/Portals/0/ISTAT%20Online/Session%20PDFs/2026_03_17%20Freighter%20Aircraft%20Market%20Outlook%20per%20Transport%20Research%20Advisory%20-PPT.pdf?ver=PDNQJFSji7Tahm9PC-BTIg%3D%3D&utm_source=openai)) - **March 2026 dynamics** - IATA’s **March 2026 report** notes continued **double‑digit demand growth** and highlights periods where passenger‑linked (belly‑hold) capacity becomes more important, as well as volatility linked to disruptions in some Middle East operations—factors that can transiently tighten capacity around Istanbul and neighboring hubs. ([iata.org](https://www.iata.org/en/iata-repository/publications/economic-reports/air-cargo-market-analysis-march-2026/?utm_source=openai)) **Istanbul‑specific capacity signals** - **Airport‑level infrastructure** - **iGA Istanbul Airport cargo hub**: ~**1.4 million m²** of cargo area; hosts **Turkish Cargo, DHL, UPS**; new freight consolidation hubs are planned under Istanbul’s SUMP, which will further streamline cargo flows and last‑mile logistics into/out of the city. ([2026.itseuropeancongress.com](https://2026.itseuropeancongress.com/about/istanbul-bridging-innovation-at-the-crossroads-of-continents/strategic-market-investment-gateway?utm_source=openai)) - **FedEx global air transit facility (IST, inaugurated September 2025)**: expands transit and sort capacity for express cargo, effectively increasing **available uplift for time‑sensitive shipments, including pharmaceuticals**, on Europe–Middle East–Asia routes via Istanbul. ([newsroom.fedex.com](https://newsroom.fedex.com/newsroom/europe-english/fedex-inaugurates-new-global-air-transit-facility-at-istanbul-airport-elevating-turkiyes-position-in-global-logistics?utm_source=openai)) - **Post‑pandemic capacity vs. demand (Europe–Middle East)** - By early 2026, **global capacity has largely recovered to or exceeded pre‑COVID levels**, but: - Strong cross‑regional trade (Asia–Europe, Middle East–Asia) and e‑commerce keep **load factors elevated** on many long‑haul routes. - The **Europe–Middle East** and **Europe–Asia** corridors—where Istanbul is a key connecting hub—show **double‑digit demand growth with capacity growth that is positive but more modest**, implying **localized capacity tightness at seasonal peaks** rather than a chronic crunch. ([iata.org](https://www.iata.org/en/publications/economics/reports/air-cargo-market-analysis-february-2026/?utm_source=openai)) **Rates and seasonal peaks (directional)** - Detailed Istanbul‑specific spot rate indices for 2026 are mostly paywalled (Tac Index, Xeneta, etc.), but combining open IATA and qualitative industry commentary: - **Seasonal peaks:** - **Late Q3–Q4 (Sept–Dec)**: traditional peak season out of Asia into Europe, with knock‑on effects via Istanbul as a routing node; rates typically firm up, and capacity constraints arise on some corridors (especially westbound flows). - **Pharma‑linked peaks**: - **Q4–Q1** (flu season and routine vaccine campaigns) and any **ad‑hoc vaccine or biologic campaign shipments** (e.g., outbreak responses) can create short‑term spikes in **temperature‑controlled capacity demand** out of/into Istanbul. - **Rate environment vs. pandemic extremes:** - 2026 spot and contract rates are **well below the pandemic peak levels of 2020–2021**, but remain **above 2018–2019 averages** on many lanes due to sustained demand growth and higher operating costs (fuel, labor). - Load factor data from IATA—demand outpacing capacity growth (e.g., **+11.2% CTK vs. +8.5% ACTK in Feb 2026**)—suggest **moderately tight markets**, especially in high‑yield segments like pharma, express, and e‑commerce. ([iata.org](https://www.iata.org/en/publications/economics/reports/air-cargo-market-analysis-february-2026/?utm_source=openai)) **Implications for pharma / cold‑chain users in Istanbul (2026)** - **Capacity availability** - With **expanded airport infrastructure (1.4 m m² cargo hub)** and new operator capacity (FedEx transit facility, growing Turkish Cargo operations), Istanbul in 2026 offers **significantly more air cargo capacity than in the immediate post‑pandemic years**, particularly for integrated pharma‑logistics solutions. ([newsroom.fedex.com](https://newsroom.fedex.com/newsroom/europe-english/fedex-inaugurates-new-global-air-transit-facility-at-istanbul-airport-elevating-turkiyes-position-in-global-logistics?utm_source=openai)) - **Risk of congestion / crunch** - Despite increased capacity, **periodic congestion risk remains**: - During **Q4 global peak** and any **regional geopolitical or operational disruptions** in neighboring Middle East hubs, volume can be diverted through Istanbul, tightening capacity and nudging rates higher. ([iata.org](https://www.iata.org/en/iata-repository/publications/economic-reports/air-cargo-market-analysis-march-2026/?utm_source=openai)) - For **temperature‑controlled and clinical‑trial shipments**, early booking of **active or passive cold‑chain solutions** and preferred‑carrier block space through Istanbul is advisable for Q4 2026 and any large campaign windows. - **Strategic takeaway for 2026–2027** - Istanbul is moving from being just a **geographical bridge** to a **deliberately developed cargo and pharma gateway**, with: - Growing **cold‑chain warehousing** (see Dimension 1). - Expanded **airside and integrator capacity**. - For exporters of **biologics, vaccines and clinical‑trial materials**, Istanbul in 2026 offers **improving connectivity and reliability**, but **not yet a surplus capacity environment**—planning around **seasonal and lane‑specific tightness** remains necessary. **Sources – Dimension 3** IATA Air Cargo Market Analyses (Dec 2025, Feb 2026, Mar 2026); Transport Research Advisory freighter outlook; ITS Europe 2026 Istanbul cargo hub profile; FedEx Istanbul transit hub press release; Turkish investment office newsletter. ([newsroom.fedex.com](https://newsroom.fedex.com/newsroom/europe-english/fedex-inaugurates-new-global-air-transit-facility-at-istanbul-airport-elevating-turkiyes-position-in-global-logistics?utm_source=openai)) Sources: • DHL Supply Chain Türkiye Opens Asia 1 Facility - DHL - Turkey https://www.dhl.com/tr-en/home/press/press-archive/2026/dhl-supply-chain-turkiye-opens-asia-1-facility.html?utm_source=openai • Arvato opens new logistics center in Istanbul | Air Freight News https://airfreight.news/articles/full/arvato-opens-new-logistics-center-in-istanbul?utm_source=openai • Arvato opens new logistics center in Istanbul | Air Freight News https://airfreight.news/articles/full/arvato-opens-new-logistics-center-in-istanbul?utm_source=openai • Turkey Pharma Cold Chain Market | 2024 – 2030 | Ken Research https://www.kenresearch.com/turkey-cold-chain-infra-for-pharma-market?utm_source=openai • Turkey Pharma Cold Chain Market | 2024 – 2030 | Ken Research https://www.kenresearch.com/turkey-cold-chain-infra-for-pharma-market?utm_source=openai • Strategic Market & Investment Gateway | ITS Istanbul https://2026.itseuropeancongress.com/about/istanbul-bridging-innovation-at-the-crossroads-of-continents/strategic-market-investment-gateway?utm_source=openai • FedEx inaugurates new global air transit facility at Istanbul Airport, elevating Türkiye’s position in global logistics https://newsroom.fedex.com/newsroom/europe-english/fedex-inaugurates-new-global-air-transit-facility-at-istanbul-airport-elevating-turkiyes-position-in-global-logistics?utm_source=openai • i | TURKISH PHARMACEUTICAL SECTOR REPORT SUMMARY https://www.aifd.org.tr/wp-content/uploads/2024/12/20241105_Turkish-pharma-sector-report-2024_Summary.pdf?utm_source=openai • DHL Supply Chain Türkiye Opens Asia 1 Facility - DHL - Turkey https://www.dhl.com/tr-en/home/press/press-archive/2026/dhl-supply-chain-turkiye-opens-asia-1-facility.html?utm_source=openai • i | TURKISH PHARMACEUTICAL SECTOR REPORT SUMMARY https://www.aifd.org.tr/wp-content/uploads/2024/12/20241105_Turkish-pharma-sector-report-2024_Summary.pdf?utm_source=openai • Turkey Exports of pharmaceutical products - 2026 Data 2027 Forecast 1989-2025 Historical https://tradingeconomics.com/turkey/exports/pharmaceutical-products?utm_source=openai • Turkey Pharmaceutical Export: Analysis 2026 - xPharma https://xpharma.com.tr/en/turkey-pharmaceutical-export?utm_source=openai • Turkish Chemical Exporters Target $35 Billion in 2026 - ChemEx World https://chemexworld.com/en/news/news/turkish-chemical-exporters-target-35-billion-in-2026?utm_source=openai • Turkey's 2026 Export Potential: Sectoral Analysis and Opportunities | Toko Trading https://www.toko.com.tr/en/blog/turkey-export-potential-2026?utm_source=openai • i | TURKISH PHARMACEUTICAL SECTOR REPORT SUMMARY https://www.aifd.org.tr/wp-content/uploads/2024/12/20241105_Turkish-pharma-sector-report-2024_Summary.pdf?utm_source=openai • Turkey Pharmaceutical Export: Analysis 2026 - xPharma https://xpharma.com.tr/en/turkey-pharmaceutical-export?utm_source=openai • Turkey Exports of pharmaceutical products - 2026 Data 2027 Forecast 1989-2025 Historical https://tradingeconomics.com/turkey/exports/pharmaceutical-products?utm_source=openai • Turkey Exports of pharmaceutical products - 2026 Data 2027 Forecast 1989-2025 Historical https://tradingeconomics.com/turkey/exports/pharmaceutical-products?utm_source=openai • Turkey Pharmaceutical Export: Analysis 2026 - xPharma https://xpharma.com.tr/en/turkey-pharmaceutical-export?utm_source=openai • Turkey's 2026 Export Potential: Sectoral Analysis and Opportunities | Toko Trading https://www.toko.com.tr/en/blog/turkey-export-potential-2026?utm_source=openai • IATA - Air Cargo Market Analysis February 2026 https://www.iata.org/en/publications/economics/reports/air-cargo-market-analysis-february-2026/?utm_source=openai • Air Cargo Market Analysis December 2025 https://mtsinsights-assets.s3.amazonaws.com/media/summaries/att/iata-air-cargo-market-analysis/2026/01/29/c63bc21f-9a82-478-ad7e-076f57e916a8.pdf?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIARB7EFOVKWBL5S67B%2F20260306%2Fus-east-2%2Fs3%2Faws4_request&X-Amz-Date=20260306T101745Z&X-Amz-Expires=3600&X-Amz-Signature=88c2c141d566a03a283bea11ee7ed8b9ff7541b2ee27c32ccb3c0a71b7623aa2&X-Amz-SignedHeaders=host&response-content-disposition=inline&response-content-type=application%2Fpdf&utm_source=openai • TRANSPORT RESEARCH ADVISORY https://www.istat.org/Portals/0/ISTAT%20Online/Session%20PDFs/2026_03_17%20Freighter%20Aircraft%20Market%20Outlook%20per%20Transport%20Research%20Advisory%20-PPT.pdf?ver=PDNQJFSji7Tahm9PC-BTIg%3D%3D&utm_source=openai • Air Cargo Market Analysis https://www.iata.org/en/iata-repository/publications/economic-reports/air-cargo-market-analysis-march-2026/?utm_source=openai • FedEx inaugurates new global air transit facility at Istanbul Airport, elevating Türkiye’s position in global logistics https://newsroom.fedex.com/newsroom/europe-english/fedex-inaugurates-new-global-air-transit-facility-at-istanbul-airport-elevating-turkiyes-position-in-global-logistics?utm_source=openai • IATA - Air Cargo Market Analysis February 2026 https://www.iata.org/en/publications/economics/reports/air-cargo-market-analysis-february-2026/?utm_source=openai • IATA - Air Cargo Market Analysis February 2026 https://www.iata.org/en/publications/economics/reports/air-cargo-market-analysis-february-2026/?utm_source=openai • FedEx inaugurates new global air transit facility at Istanbul Airport, elevating Türkiye’s position in global logistics https://newsroom.fedex.com/newsroom/europe-english/fedex-inaugurates-new-global-air-transit-facility-at-istanbul-airport-elevating-turkiyes-position-in-global-logistics?utm_source=openai • Air Cargo Market Analysis https://www.iata.org/en/iata-repository/publications/economic-reports/air-cargo-market-analysis-march-2026/?utm_source=openai • FedEx inaugurates new global air transit facility at Istanbul Airport, elevating Türkiye’s position in global logistics https://newsroom.fedex.com/newsroom/europe-english/fedex-inaugurates-new-global-air-transit-facility-at-istanbul-airport-elevating-turkiyes-position-in-global-logistics?utm_source=openai